Last reviewed · How we verify
ABS-201 SC Multiple Doses
At a glance
| Generic name | ABS-201 SC Multiple Doses |
|---|---|
| Sponsor | Absci Pty Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Healthy Adults With and Without Androgenetic Alopecia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABS-201 SC Multiple Doses CI brief — competitive landscape report
- ABS-201 SC Multiple Doses updates RSS · CI watch RSS
- Absci Pty Ltd. portfolio CI